| NCT03409692 |
Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients |
https://ClinicalTrials.gov/show/NCT03409692 |
Active, not recruiting |
University of Turin, Italy |
2017-11-30 |
| NCT03406091 |
Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients |
https://ClinicalTrials.gov/show/NCT03406091 |
Recruiting |
Fondazione Neoplasie Sangue Onlus |
2020-02-28 |
| NCT03405571 |
Validation of the 4TS RAM in the Prevention of Venous Thromboembolism in Patients With Plasma Cell Dyscrasias. |
https://ClinicalTrials.gov/show/NCT03405571 |
Recruiting |
University of Athens |
2020-06-30 |
| NCT03353545 |
Retrospective and Prospective Study of POmalidomide Plus LoW Dose Dexa Efficacy in RRMM Patients Under Real-Life Conditions |
https://ClinicalTrials.gov/show/NCT03353545 |
Completed |
Genesis Pharma S.A. |
2020-02-21 |
| NCT03288974 |
Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea |
https://ClinicalTrials.gov/show/NCT03288974 |
Recruiting |
Celgene |
2023-06-08 |
| NCT03276481 |
Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation |
https://ClinicalTrials.gov/show/NCT03276481 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2020-08-28 |
| NCT03210753 |
Study of Risk Factors and Genetic Association With Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT03210753 |
Recruiting |
National Taiwan University Hospital |
2020-07-31 |
| NCT03200626 |
Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT03200626 |
Active, not recruiting |
Medical College of Wisconsin |
2021-09-24 |
| NCT03190525 |
Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT03190525 |
Active, not recruiting |
Gruppo Italiano Malattie EMatologiche dell’Adulto |
2019-01-02 |
| NCT03188536 |
Clinical and Sociodemographic Characterization of Multiple Myeloma Patients With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study) |
https://ClinicalTrials.gov/show/NCT03188536 |
Completed |
Takeda |
2018-11-15 |
| NCT03169361 |
NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) “Relapsed/Refractory Multiple Myeloma” |
https://ClinicalTrials.gov/show/NCT03169361 |
Active, not recruiting |
Takeda |
2021-03-31 |
| NCT03127761 |
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT03127761 |
Recruiting |
Center for International Blood and Marrow Transplant Research |
2027-05-31 |
| NCT03006315 |
Mobile Health Device Study for Myeloma Patients |
https://ClinicalTrials.gov/show/NCT03006315 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-06-30 |
| NCT03001804 |
Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients |
https://ClinicalTrials.gov/show/NCT03001804 |
Recruiting |
Celgene |
2021-12-30 |
| NCT02997813 |
Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies |
https://ClinicalTrials.gov/show/NCT02997813 |
Completed |
Intergroupe Francophone du Myelome |
2015-12-31 |
| NCT02976493 |
Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT02976493 |
Completed |
Bristol-Myers Squibb |
2018-06-18 |
| NCT02976272 |
Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple |
https://ClinicalTrials.gov/show/NCT02976272 |
Recruiting |
University Hospital, Clermont-Ferrand |
2020-12-31 |
| NCT02970747 |
Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone in Multiple Myeloma Patients |
https://ClinicalTrials.gov/show/NCT02970747 |
Active, not recruiting |
iOMEDICO AG |
2022-12-23 |
| NCT02946333 |
A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain |
https://ClinicalTrials.gov/show/NCT02946333 |
Recruiting |
Celgene |
2020-10-10 |
| NCT02922543 |
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use |
https://ClinicalTrials.gov/show/NCT02922543 |
Active, not recruiting |
Celgene |
2020-06-19 |
| NCT02918695 |
Comparison of Geriatric Screening Methods in Newly Diagnosed Multiple Myeloma Patients |
https://ClinicalTrials.gov/show/NCT02918695 |
Recruiting |
Universitaire Ziekenhuizen Leuven |
2019-12-31 |
| NCT02917239 |
Prevalence of Ocular Disorders in Multiple Myeloma (MM-OO-16) |
https://ClinicalTrials.gov/show/NCT02917239 |
Completed |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2016-09-30 |
| NCT02902900 |
An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice |
https://ClinicalTrials.gov/show/NCT02902900 |
Recruiting |
Celgene |
2019-09-30 |
| NCT02892383 |
Quality of Life the Danish Multiple Myeloma Patients |
https://ClinicalTrials.gov/show/NCT02892383 |
Recruiting |
Odense University Hospital |
2022-09-01 |
| NCT02884102 |
MMRF Molecular Profiling Protocol |
https://ClinicalTrials.gov/show/NCT02884102 |
Recruiting |
Multiple Myeloma Research Foundation |
2023-06-30 |
| NCT02861287 |
Economic Evaluation of the Use of Plerixafor for Autologous HSC Transplantation for Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT02861287 |
Completed |
Institut Paoli-Calmettes |
2015-12-31 |
| NCT02761187 |
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants |
https://ClinicalTrials.gov/show/NCT02761187 |
Active, not recruiting |
Takeda |
2024-07-01 |
| NCT02741999 |
A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early |
https://ClinicalTrials.gov/show/NCT02741999 |
Completed |
Tufts Medical Center |
2020-04-05 |
| NCT02741544 |
Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM]) |
https://ClinicalTrials.gov/show/NCT02741544 |
Active, not recruiting |
Celgene |
2021-08-21 |
| NCT02726750 |
Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies |
https://ClinicalTrials.gov/show/NCT02726750 |
Recruiting |
M.D. Anderson Cancer Center |
2021-12-31 |
| NCT02671448 |
Pilot Trial of Homebound Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02671448 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-01-31 |
| NCT02627261 |
Multiple Myeloma Minimal Residual Disease |
https://ClinicalTrials.gov/show/NCT02627261 |
Recruiting |
Hospices Civils de Lyon |
2022-05-31 |
| NCT02608515 |
A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease |
https://ClinicalTrials.gov/show/NCT02608515 |
Completed |
Genesis Pharma S.A. |
2016-09-30 |
| NCT01109407 |
Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM) |
https://ClinicalTrials.gov/show/NCT01109407 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT02559583 |
Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin’s Lymphoma (NHL) in Latin America |
https://ClinicalTrials.gov/show/NCT02559583 |
Completed |
Janssen-Cilag Ltd. |
2016-06-30 |
| NCT02555839 |
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice |
https://ClinicalTrials.gov/show/NCT02555839 |
Recruiting |
Celgene |
2022-09-30 |
| NCT02556905 |
A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea |
https://ClinicalTrials.gov/show/NCT02556905 |
Completed |
Celgene |
2016-11-30 |
| NCT02537808 |
Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT02537808 |
Active, not recruiting |
iOMEDICO AG |
2020-09-30 |
| NCT02474563 |
Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT02474563 |
Completed |
Janssen Korea, Ltd., Korea |
2014-05-31 |
| NCT02474160 |
Collection and Storage of Tissue and Blood Samples From Patients With Cancer |
https://ClinicalTrials.gov/show/NCT02474160 |
Recruiting |
National Cancer Institute (NCI) |
2021-05-04 |
| NCT02439476 |
Non-interventional Study on Salvage Auto in Relapsed Myeloma |
https://ClinicalTrials.gov/show/NCT02439476 |
Active, not recruiting |
Association for Training, Education, and Research in Hematology, Immunology, and Transplantation |
2020-06-08 |
| NCT02403102 |
Imageguided Theranostics in Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT02403102 |
Active, not recruiting |
Institute of Cancer Research, United Kingdom |
2020-03-31 |
| NCT02387879 |
A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR |
https://ClinicalTrials.gov/show/NCT02387879 |
Active, not recruiting |
Celgene |
2021-12-31 |
| NCT02294487 |
Study of the Immune Response After Vaccination in Multiple Myeloma Patients |
https://ClinicalTrials.gov/show/NCT02294487 |
Completed |
Aurora Health Care |
2016-01-28 |
| NCT02269592 |
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome |
https://ClinicalTrials.gov/show/NCT02269592 |
Recruiting |
Dana-Farber Cancer Institute |
2024-12-31 |
| NCT02212262 |
Role of Osteocytes in Myeloma Bone Disease |
https://ClinicalTrials.gov/show/NCT02212262 |
Recruiting |
Indiana University |
2019-06-30 |
| NCT02187731 |
Functional Imaging in Multiple Myeloma -PET/CT and Diffusion Weighted Imaging in Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT02187731 |
Active, not recruiting |
Odense University Hospital |
2019-12-31 |
| NCT02095379 |
Oligosecretary Myeloma: Prevalence and Its Clinical Significance |
https://ClinicalTrials.gov/show/NCT02095379 |
Completed |
Samsung Medical Center |
2013-12-31 |
| NCT02026505 |
Evaluation of Cardiotoxic Effects of Bortezomib |
https://ClinicalTrials.gov/show/NCT02026505 |
Completed |
Oregon Health and Science University |
2016-12-31 |
| NCT02075996 |
Non-interventional Study With Pomalidomide (Imnovid®) |
https://ClinicalTrials.gov/show/NCT02075996 |
Active, not recruiting |
iOMEDICO AG |
2021-03-31 |
| NCT02033928 |
Comprehensive Frailty Assessment |
https://ClinicalTrials.gov/show/NCT02033928 |
Completed |
Ohio State University Comprehensive Cancer Center |
2017-08-31 |
| NCT01838512 |
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) |
https://ClinicalTrials.gov/show/NCT01838512 |
Recruiting |
Bristol-Myers Squibb |
2024-06-13 |
| NCT01820546 |
Cancer Stem Cells in Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01820546 |
Completed |
Ankara University |
2016-01-31 |
| NCT01746030 |
Geriatric Assessments in Senior Adults With Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01746030 |
Completed |
Washington University School of Medicine |
2014-12-31 |
| NCT01697839 |
Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients |
https://ClinicalTrials.gov/show/NCT01697839 |
Completed |
Oncotherapeutics |
2015-08-31 |
| NCT01675245 |
An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade |
https://ClinicalTrials.gov/show/NCT01675245 |
Completed |
Xian-Janssen Pharmaceutical Ltd. |
2010-05-31 |
| NCT01622582 |
Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01622582 |
Completed |
University of Arkansas |
2013-03-31 |
| NCT01572857 |
Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01572857 |
Completed |
Rennes University Hospital |
2018-01-31 |
| NCT01508416 |
Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01508416 |
Completed |
Centre Hospitalier Universitaire de Saint Etienne |
2014-12-31 |
| NCT01472627 |
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro |
https://ClinicalTrials.gov/show/NCT01472627 |
Completed |
Dana-Farber Cancer Institute |
2018-01-31 |
| NCT01454297 |
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile |
https://ClinicalTrials.gov/show/NCT01454297 |
Active, not recruiting |
Multiple Myeloma Research Foundation |
2023-09-30 |
| NCT01440556 |
Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01440556 |
Completed |
Azienda Ospedaliera San Giovanni Battista |
2013-01-31 |
| NCT01430546 |
Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line |
https://ClinicalTrials.gov/show/NCT01430546 |
Completed |
Karolinska University Hospital |
2016-01-31 |
| NCT01410981 |
Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01410981 |
Completed |
Medical University of South Carolina |
2014-06-30 |
| NCT04393090 |
eHealth for the Elderly |
https://ClinicalTrials.gov/show/NCT04393090 |
Completed |
Cankado Service GmbH |
2017-05-31 |
| NCT04328662 |
Ninlaro Intensive Drug Monitoring Protocol |
https://ClinicalTrials.gov/show/NCT04328662 |
Recruiting |
Takeda |
2024-10-31 |
| NCT04273425 |
Bone Pain in Multiple Myeloma- a Translational Study |
https://ClinicalTrials.gov/show/NCT04273425 |
Recruiting |
Sheffield Teaching Hospitals NHS Foundation Trust |
2020-12-31 |
| NCT04260490 |
Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study. |
https://ClinicalTrials.gov/show/NCT04260490 |
Recruiting |
Centre Hospitalier Universitaire de Pointe-a-Pitre |
2022-11-30 |
| NCT04242121 |
The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood |
https://ClinicalTrials.gov/show/NCT04242121 |
Recruiting |
St. Petersburg State Pavlov Medical University |
2023-01-31 |
| NCT04221178 |
Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission |
https://ClinicalTrials.gov/show/NCT04221178 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2022-01-03 |
| NCT04151615 |
VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT04151615 |
Recruiting |
Boryung Pharmaceutical Co., Ltd |
2022-09-30 |
| NCT04137523 |
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression |
https://ClinicalTrials.gov/show/NCT04137523 |
Recruiting |
University of Turin, Italy |
2019-08-12 |
| NCT04135079 |
Immune Profiling in Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT04135079 |
Recruiting |
University of Turin, Italy |
2021-04-01 |
| NCT04122092 |
Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT04122092 |
Recruiting |
Shanghai Changzheng Hospital |
2021-10-20 |
| NCT04035226 |
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment |
https://ClinicalTrials.gov/show/NCT04035226 |
Recruiting |
Janssen-Cilag Ltd. |
2022-04-28 |
| NCT04045561 |
Development of a Standardized Reference Guide for Tuning Adherence to Dispense During a Initial Pharmaceutical Consulting (CP ) to the Patient With Multiple Myeloma Oral Chemotherapy Primocure |
https://ClinicalTrials.gov/show/NCT04045561 |
Completed |
Centre Hospitalier Universitaire de NÄ«mes |
2016-12-31 |
| NCT04004338 |
Carfilzomib in Combination for the Treatment of RR MM |
https://ClinicalTrials.gov/show/NCT04004338 |
Recruiting |
Black Sea Hematology Association |
2021-04-14 |
| NCT03966443 |
Fluciclovine PET/CT in Multiple Myeloma Patients |
https://ClinicalTrials.gov/show/NCT03966443 |
Recruiting |
Oslo University Hospital |
2020-01-31 |
| NCT03983486 |
Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT03983486 |
Recruiting |
Centre Hospitalier Universitaire, Amiens |
2020-11-30 |
| NCT03951220 |
The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss |
https://ClinicalTrials.gov/show/NCT03951220 |
Recruiting |
Oxford University Hospitals NHS Trust |
2020-12-30 |
| NCT03890614 |
Novel 3D Myeloma Organoid to Study Disease Biology and Chemosensitivity |
https://ClinicalTrials.gov/show/NCT03890614 |
Recruiting |
Wake Forest University Health Sciences |
2020-07-31 |
| NCT03848676 |
Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT03848676 |
Recruiting |
University of Turin, Italy |
2023-07-01 |
| NCT03779555 |
Lenalidomide Adherence in Older Adults |
https://ClinicalTrials.gov/show/NCT03779555 |
Recruiting |
Washington University School of Medicine |
2020-09-30 |
| NCT03777410 |
Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT03777410 |
Recruiting |
Travera LLC |
2021-01-31 |
| NCT03702088 |
Place of the Hevylite Test in the Evaluation of MRD in Myeloma |
https://ClinicalTrials.gov/show/NCT03702088 |
Recruiting |
University Hospital, Montpellier |
2020-12-01 |
| NCT03689595 |
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE) |
https://ClinicalTrials.gov/show/NCT03689595 |
Recruiting |
Dana-Farber Cancer Institute |
2033-10-31 |
| NCT03638232 |
Myeloma Treatment in Real Life |
https://ClinicalTrials.gov/show/NCT03638232 |
Completed |
University Hospital, Toulouse |
2015-09-30 |
| NCT03618212 |
MRI in Multiple Myeloma: Analysis of the Axial Skeleton Versus Whole Body. What is the Required Analysis? |
https://ClinicalTrials.gov/show/NCT03618212 |
Recruiting |
Centre Hospitalier Universitaire de NÄ«mes |
2020-05-30 |
| NCT03616483 |
Collection of Specimens and Clinical Data to Create A Bio-repository for Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT03616483 |
Recruiting |
Indiana University |
2023-06-30 |
| NCT03602755 |
A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain |
https://ClinicalTrials.gov/show/NCT03602755 |
Completed |
Celgene |
2019-01-18 |
| NCT03537222 |
Quality of Life in Patients With Multiple Myeloma-validation Study |
https://ClinicalTrials.gov/show/NCT03537222 |
Recruiting |
Zurich University of Applied Sciences |
2020-10-31 |
| NCT03506386 |
Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis |
https://ClinicalTrials.gov/show/NCT03506386 |
Completed |
Takeda |
2019-11-08 |
| NCT03493737 |
Cost-Utility Analysis Hospital Versus Home in Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT03493737 |
Active, not recruiting |
Central Hospital, Nancy, France |
2019-08-15 |
| NCT03490084 |
Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT03490084 |
Recruiting |
Assistance Publique - Hôpitaux de Paris |
2022-10-31 |
| NCT03477643 |
Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM) |
https://ClinicalTrials.gov/show/NCT03477643 |
Recruiting |
PETHEMA Foundation |
2020-09-30 |
| NCT03433365 |
Monitoring of Deep of Response During Lenalidomide Maintenance in MM Patients Achieving at Least Very Good Partial Response (MRD) |
https://ClinicalTrials.gov/show/NCT03433365 |
Completed |
Fondazione Neoplasie Sangue Onlus |
2016-03-31 |
| NCT03433001 |
A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone |
https://ClinicalTrials.gov/show/NCT03433001 |
Active, not recruiting |
Takeda |
2021-05-31 |
| NCT03421132 |
Multiple Myeloma Molecular Monitoring Study |
https://ClinicalTrials.gov/show/NCT03421132 |
Recruiting |
Horizon Health Network |
2022-12-31 |
| NCT01268774 |
Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide. |
https://ClinicalTrials.gov/show/NCT01268774 |
Completed |
LEO Pharma |
2011-05-31 |
| NCT01241396 |
A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure |
https://ClinicalTrials.gov/show/NCT01241396 |
Completed |
Janssen Pharmaceutica N.V., Belgium |
2014-11-30 |
| NCT01234129 |
Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01234129 |
Completed |
Instituto Mexicano del Seguro Social |
2009-12-31 |
| NCT01199562 |
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01199562 |
Completed |
City of Hope Medical Center |
2013-12-31 |
| NCT01177527 |
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders |
https://ClinicalTrials.gov/show/NCT01177527 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2021-01-31 |
| NCT01137825 |
Registry of Older Patients With Cancer |
https://ClinicalTrials.gov/show/NCT01137825 |
Active, not recruiting |
UNC Lineberger Comprehensive Cancer Center |
2030-06-30 |
| NCT01137643 |
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT01137643 |
Active, not recruiting |
UNC Lineberger Comprehensive Cancer Center |
2040-07-31 |
| NCT01132833 |
Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy |
https://ClinicalTrials.gov/show/NCT01132833 |
Completed |
UNC Lineberger Comprehensive Cancer Center |
2012-12-31 |
| NCT01081028 |
Connect® MM- The Multiple Myeloma Disease Registry |
https://ClinicalTrials.gov/show/NCT01081028 |
Active, not recruiting |
Celgene |
2024-12-31 |
| NCT01079429 |
Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM. |
https://ClinicalTrials.gov/show/NCT01079429 |
Active, not recruiting |
Rennes University Hospital |
2014-01-31 |
| NCT01060202 |
Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib |
https://ClinicalTrials.gov/show/NCT01060202 |
Completed |
Janssen Korea, Ltd., Korea |
2011-07-31 |
| NCT01030302 |
A Retreatment Study With Bortezomib for Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01030302 |
Completed |
Janssen Korea, Ltd., Korea |
2010-09-30 |
| NCT01026701 |
Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients. |
https://ClinicalTrials.gov/show/NCT01026701 |
Completed |
Janssen Korea, Ltd., Korea |
2009-11-30 |
| NCT01021592 |
Quality of Life in Multiple Myeloma Patients Treated With Bortezomib |
https://ClinicalTrials.gov/show/NCT01021592 |
Completed |
Janssen Korea, Ltd., Korea |
2008-07-31 |
| NCT01006070 |
Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine |
https://ClinicalTrials.gov/show/NCT01006070 |
Completed |
University of California, San Francisco |
2011-03-31 |
| NCT00993694 |
Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone |
https://ClinicalTrials.gov/show/NCT00993694 |
Completed |
Vanderbilt University Medical Center |
2009-12-31 |
| NCT00964821 |
Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00964821 |
Completed |
City of Hope Medical Center |
2013-05-31 |
| NCT00919139 |
S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. |
https://ClinicalTrials.gov/show/NCT00919139 |
Completed |
Southwest Oncology Group |
2010-11-30 |
| NCT00910078 |
Serum Free Light Change in Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00910078 |
Completed |
Azienda Ospedaliera San Giovanni Battista |
NA |
| NCT00911105 |
Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone |
https://ClinicalTrials.gov/show/NCT00911105 |
Completed |
iOMEDICO AG |
2012-04-30 |
| NCT00900406 |
Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00900406 |
Completed |
Vanderbilt-Ingram Cancer Center |
2010-03-31 |
| NCT00900263 |
S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma |
https://ClinicalTrials.gov/show/NCT00900263 |
Completed |
Southwest Oncology Group |
2016-04-30 |
| NCT00899080 |
Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide |
https://ClinicalTrials.gov/show/NCT00899080 |
Completed |
Eastern Cooperative Oncology Group |
2008-08-04 |
| NCT00898066 |
S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease |
https://ClinicalTrials.gov/show/NCT00898066 |
Completed |
Southwest Oncology Group |
2007-06-30 |
| NCT00898040 |
Study of DNA Samples From Patients With Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00898040 |
Completed |
Eastern Cooperative Oncology Group |
2007-01-01 |
| NCT00874211 |
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases |
https://ClinicalTrials.gov/show/NCT00874211 |
Completed |
Southwest Oncology Group |
2019-06-30 |
| NCT02394210 |
Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT02394210 |
Active, not recruiting |
Celgene |
2021-01-31 |
| NCT03091127 |
Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe |
https://ClinicalTrials.gov/show/NCT03091127 |
Completed |
Amgen |
2020-03-17 |
| NCT02849444 |
A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance |
https://ClinicalTrials.gov/show/NCT02849444 |
Active, not recruiting |
Celgene |
2019-12-23 |
| NCT00741780 |
Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662). |
https://ClinicalTrials.gov/show/NCT00741780 |
Completed |
Sanofi |
2011-07-31 |
| NCT00688168 |
Inflammatory Cytokines in Symptom Production in Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00688168 |
Completed |
M.D. Anderson Cancer Center |
2019-01-08 |
| NCT00639054 |
The Molecular Characterization of Multiple Myeloma at Relapse |
https://ClinicalTrials.gov/show/NCT00639054 |
Completed |
Rigshospitalet, Denmark |
2014-12-31 |
| NCT00572338 |
Therapeutic Research in Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00572338 |
Completed |
University of Arkansas |
2015-03-31 |
| NCT00505999 |
Etiology of Multiple Myeloma: A Case-Control Study |
https://ClinicalTrials.gov/show/NCT00505999 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-07-31 |
| NCT00476294 |
Long-Term Follow Up Study for AMD3100 Patients |
https://ClinicalTrials.gov/show/NCT00476294 |
Completed |
M.D. Anderson Cancer Center |
2012-07-31 |
| NCT00440635 |
Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00440635 |
Completed |
Janssen-Cilag International NV |
NA |
| NCT00339963 |
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00339963 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00290095 |
Quality of Life in Patients With Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00290095 |
Completed |
Oslo University Hospital |
2008-06-30 |
| NCT00281814 |
Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant |
https://ClinicalTrials.gov/show/NCT00281814 |
Completed |
The Cleveland Clinic |
2008-12-31 |
| NCT00281801 |
Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation |
https://ClinicalTrials.gov/show/NCT00281801 |
Completed |
Case Comprehensive Cancer Center |
2008-12-31 |
| NCT00048958 |
Cytogenetic Studies in Acute Leukemia and Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00048958 |
Active, not recruiting |
Alliance for Clinical Trials in Oncology |
2100-01-31 |